Enter your email to access this webinar
About the Webinar
Clinical trial simulation is rapidly emerging as a critical component of strategic planning for clinical development teams. It allows them to rigorously test hypotheses prior to initiating actual trials.
According to recent data from QuantHealth, simulations have demonstrated an 80-90% accuracy rate in predicting whether trial outcomes will be positive or negative. These insights enable teams to refine cohort selection, inform go/no-go decisions, and identify promising opportunities for drug repurposing.
In this 30-minute online event, hosted by Adam Petrich, MD, we will explore the specifics behind this impressive statistic and discuss how simulation-driven approaches can help improve decision-making, and shorten development timelines particularly at the transition from early-phase studies to pivotal trials.
Agenda
● Interpreting QuantHealth’s accuracy benchmarks for predictive trial simulations.
● Exploring practical applications for optimizing cohort planning and go/no-go decisions.
● Leveraging simulations to surpass the current 28.9% success rate in Phase II trials.
Meet the Speakers
Adam has extensive experience in all stages of oncology drug development (ranging from pre-IND to NDA/BLA), across a range of platforms (small molecules, mAb/ADC, immuno-oncology), spanning both solid tumors and hematologic malignancies. He has worked for and with many of today’s most innovative pharmaceutical companies, including AbbVie, Daiichi-Sankyo, AstraZeneca, and Roche/Genentech, and has extensive cross-functional and leadership experience and leadership, including clinical and commercial development, regulatory and medical affairs, business development, and and BD/licensing. He is trained as a hematologist and medical oncologist, and prior to joining the pharmaceutical industry, specialized in developmental therapeutics as a faculty member at the Feinberg School of Medicine and the Lurie Cancer Center, both at Northwestern University in Chicago.